No effects of nirmatrelvir/ritonavir on darunavir plasma trough concentrations: a case report

被引：0

作者：

Cattaneo, Dario ^{[1
]}

Pagano, Simone ^{[1
]}

Lazzarin, Samuel ^{[1
]}

Calvagna, Nunziata ^{[1
]}

Gervasoni, Cristina ^{[1
]}

机构：

[1] ASST Fatebenefratelli Sacco, I-20157 Milan, Italy

来源：

EUROPEAN JOURNAL OF HOSPITAL PHARMACY | 2025年 / 32卷 / 01期

关键词：

COMMUNICABLE DISEASES; COVID-19; DRUG INCOMPATIBILITY; Case Reports; Clinical Competence; Drug Monitoring; EFFICACY; SAFETY;

D O I：

10.1136/ejhpharm-2023-004015

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

COVID-19 may be associated with worst outcomes in people living with HIV compared with HIV-negative patients. Nirmatrelvir/ritonavir can be safely co-administered with all the HIV antiretroviral drugs, without considering dose adjustment. However, no studies have formally investigated the effect of a double booster (ritonavir plus cobicistat) regimen on darunavir concentrations. We presented a case describing the lack of effects of adding nirmatrelvir/ritonavir on darunavir plasma trough concentrations in a patient with HIV already on treatment with a booster-based antiretroviral regimen. We believe this could be a reassuring message for physicians, allowing them to prevent unnecessary denial of COVID-19 treatment or inappropriate discontinuation of co-medications in patients with HIV.

引用

页码：87 / 88

页数：2

共 11 条

[1] COVID-19 outcomes in HIV patients: A review [J].

Aborode, Abdullahi Tunde ;

Olotu, Titilayo Mabel ;

Oyetunde, O. B. ;

Ajagbe, Abayomi Oyeyemi ;

Mustapha, Mariam Ayoola ;

Karra-Aly, Ayah ;

Oko, Christian Inya .

ANNALS OF MEDICINE AND SURGERY, 2022, 78

[2]

[Anonymous], 2023, Epidemiological Update: West Nile Virus Transmission Season in Europe

[3]

[Anonymous], 2023, PAXLOVID SUMMARY PRO

[4] Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96 [J].

Arasteh, Keikawus ;

Yeni, Patrick ;

Pozniak, Anton ;

Grinsztejn, Beatriz ;

Jayaweera, Dushyantha ;

Roberts, Afsoon ;

Hoy, Jennifer ;

De Meyer, Sandra ;

Vangeneugden, Tony ;

Tomaka, Frank .

ANTIVIRAL THERAPY, 2009, 14 (06) :859-864

[5] Week 96 Efficacy, Virology and Safety of Darunavir/r Versus Lopinavir/r in Treatment-Experienced Patients in TITAN [J].

Banhegyi, Denes ;

Katlama, Christine ;

da Cunha, Clovis Arns ;

Schneider, Stefan ;

Rachlis, Anita ;

Workman, Cassy ;

De Meyer, Sandra ;

Vandevoorde, Ann ;

Van de Casteele, Tom ;

Tomaka, Frank .

CURRENT HIV RESEARCH, 2012, 10 (02) :171-181

[6] Management of Polypharmacy and Drug-Drug Interactions in HIV Patients: A 2-year Experience of a Multidisciplinary Outpatient Clinic [J].

Gervasoni, Cristina ;

Formenti, Tiziana ;

Cattaneo, Dario .

AIDS REVIEWS, 2019, 21 (01) :40-49

[7]

Hoetelmans RM., 2003, 10 C RETR OPP INF FD

[8] Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir [J].

Kakuda, Thomas N. ;

Brochot, Anne ;

Tomaka, Frank L. ;

Vangeneugden, Tony ;

Van De Casteele, Tom ;

Hoetelmans, Richard M. W. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (10) :2591-2605

[9] Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications [J].

Marzolini, Catia ;

Kuritzkes, Daniel R. ;

Marra, Fiona ;

Boyle, Alison ;

Gibbons, Sara ;

Flexner, Charles ;

Pozniak, Anton ;

Boffito, Marta ;

Waters, Laura ;

Burger, David ;

Back, David J. ;

Khoo, Saye .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (06) :1191-1200

[10]

Sekar V., 2006, 16 INT AIDS C TOR

← 1 2 →